Strategic expansion AtomVie is rapidly expanding its manufacturing footprint with a new state-of-the-art facility in Hamilton, Ontario, and has announced large-scale facility openings in Canada, signaling heightened global supply capabilities and potential for new regional CDMO collaborations and capacity-based service offerings.

Spinout momentum As a McMaster CPDC spinout with substantial clinical development experience and a track record of transferring technology across 70+ programs, AtomVie presents opportunities to partner on early to late-phase radiopharmaceutical programs leveraging their regulatory, quality, and logistics capabilities.

Scale potential With a revenue range of one to several billions and a growing workforce beyond 200 by end of 2026, AtomVie demonstrates scalable operations that can absorb additional radiopharmaceutical projects, enabling co-development, manufacturing, and fill-finish partnerships for commercial supply.

Global reach The company provides radiopharmaceutical GMP manufacturing and worldwide distribution, creating openings for multinational clinical trials, cross-border regulatory support, and logistics partnerships to ensure reliable, on-time delivery to 28 countries.

Investor and credibility Active participation in investor events and substantial funding signals financial strength and market confidence, presenting a compelling case for strategic investments or long-term manufacturing contracts with potential for favorable terms and accelerated scale-up.